Skip to ContentSkip to Navigation
About us Latest news News News articles

Towards a cross-protective influenza vaccine

12 December 2012

PhD ceremony: Ms. N. van Braeckel Budimir, 14.30 uur, Academiegebouw, Broerstraat 5, Groningen

Dissertation: Towards a cross-protective influenza vaccine

Promotor(s): prof. J.C. Wilschut, prof. A.L.W. Huckriede

Faculty: Medical Sciences

Although vaccination is the cornerstone of influenza prevention, and current inactivated influenza vaccines are safe, there is an increasing demand for further improvement of these vaccines. Indeed, influenza vaccine efficacy is suboptimal in a number of important target groups for vaccination, particularly the elderly and young children.

Current influenza vaccines induce a narrow and strain-specific immune response and fail to protect against different antigenic variants and subtypes. Therefore, development of vaccines capable of inducing a broadly protective immune response is required. One possible approach, addressed in this thesis, is to aim for induction of cross-protective Cytotoxic T-Lymphocytes (CTLs) specific for antigenic determinants that are conserved among different influenza variants and subtypes. This study demonstrates that Whole Inactivated Influenza (WIV) vaccine has the capacity to induce heterosubtypic cross-protection, mainly mediated by CTLs. CTL-inducing capacity of WIV is highly influenced by the virus inactivation method, as some treatments, such as Formalin-inactivation, severely compromise membrane fusion activity of WIV, required for successful delivery of antigen into the cytosol of antigen-presenting cell. Furthermore, we showed that heterosubtypic cross-protection induced by WIV vaccination critically depends on activation of Toll-like receptor 7 (TLR7) in dendritic cells, which is required for successful antigen cross-presentation. Finally, our results show that parenteral routes of WIV administration are superior in comparison to mucosal vaccination in terms of induction of cross-protective CTL responses. Taken together, our findings appear to support reconsideration of WIV as a “novel” vaccine formulation for induction of broadly protective immunity against influenza.

Last modified:13 March 2020 01.02 a.m.
Share this Facebook LinkedIn
View this page in: Nederlands

More news

  • 06 June 2025

    India-Netherlands Hydrogen Valley Fellowship Programme announced

    To coincide with World Environment Day, 5 June 2025, the Indian Department of Science and Technology and the University of Groningen yesterday announced a Hydrogen Valley Fellowship Programme Partnership, allowing talented Indian scholars working on...

  • 28 May 2025

    Gaan avondmensen cognitief sneller achteruit dan ochtendmensen?

    Wie ’s avonds opleeft en laat naar bed gaat, heeft een grotere kans op cognitieve achteruitgang dan een ochtendmens, blijkt uit UMCG-onderzoek.

  • 27 May 2025

    An adventure in the brain

    In the exhibition Brainstorm in the University Mueseum, Iris Sommer and two other brain researchers from Groningen explain the gut-brain connection, how it was discovered that the brain does what it does, and how games motivate you to perform...